Aldesleukin Completed Phase 2 Trials for Stage IV Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00726739Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma